drug

budoprutug

1 story · latest Aug 6, 2026

Status: Investigational
Code: TNT119
Trials: 3 registered trials in coverage

Relationships

Developed by Climb Bio, Inc.

Timeline

Climb Bio reports Q2 2026 results, sets CLYM116 R&D event and Phase 2 start

Aug 6Quarterly updateClimb Bio, Inc.

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.